Mainstream

Novartis Beats Q4 Top Line And Bottom Line Estimates; Initiates Fy25 Soft Outlook

Novartis beats Q4 top-line and bottom-line estimates; initiates FY25 soft outlook

Novartis beats Q4 top-line and bottom-line estimates; initiates FY25 soft outlook

Post Contentnvs, nvsefRead More

You might also be interested in reading SEC approves Nasdaq’s move to support tokenized securities trading.

January 31, 2025
In Mainstream